A $1 Stock With A Handsome Reward To Risk Profile

A $1 Stock With A Handsome Reward To Risk Profile

Immunic, Inc. (IMUX) traded 30.7 million shares on Wednesday, an overwhelming number compared to its daily average of close to 1 million. The spike in volume was accompanied by a little move in the stock price, up 9 cents (+6.16...
read more
Profit Taking And A Pivot Is The Preferred Path Higher

Profit Taking And A Pivot Is The Preferred Path Higher

Markets are rallying after traveling down the road and flirting with disaster (a little 80’s southern rock reference) at 10,250. We thought the NASDAQ was poised to head higher but expected a little more of a fight from sellers as...
read more
New Year Brings New Hope

New Year Brings New Hope

The New Year brings in fresh hopes for something better. We make resolutions. I am really going to lose those extra pounds this year, by the way, where are the M&Ms? We want to turn the page on the year...
read more
A Baby Biotech With Insider Buying

A Baby Biotech With Insider Buying

Wall Street showed some life last week, finishing the week in the plus column for the first time in a while. Despite gains, insiders played it cautious as buyers mostly stayed on the sidelines. The insider purchase that lit up...
read more
Some Red Before We See More Green

Some Red Before We See More Green

It looks like the NASDAQ could be headed for a cooling off period. The index’s chart appears to be rolling over for some potential profit taking. It’s not surprising considering the NASDAQ has been skirting along a borderline overbought reading...
read more
4 Undervalued Biotech Stocks To Add To Your Buy List

4 Undervalued Biotech Stocks To Add To Your Buy List

read more
7 Small-Cap Biotech Stocks To Watch For Upcoming Catalysts

7 Small-Cap Biotech Stocks To Watch For Upcoming Catalysts

Small-cap stocks in the biotech space have been in a slump, but these could see big moves Ever since “meme stock madness” screeched to a halt, small-cap stocks have been in a slump. That’s been especially the case for speculative...
read more